Publications by authors named "J Bedke"

Claim this Profile
F
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
R J Motzer, B Escudier, M Burotto, T Powles, A B Apolo, J Bedke

Ann Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Marcio Covas Moschovas, Mischa Dohler, Mohamad Omar Al Kalaa, and Vipul Patel's Letter to the Editor re: Bhaskar K. Somani, Jens Rassweiler, Evangelos Liatsikos, et al. European Association of Urology Policy on Telesurgery. Eur Urol 2025;88:318-24.
Bhaskar K Somani, Jens Rassweiler, Evangelos Liatsikos, Alexandre Mottrie, Thomas Knoll, Jens Bedke

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCC.
Lena-Sophie Menig-Benzig, Viktoria Stühler, Pascale Mazzola, Hannah Heinrich, Ute Hofmann, Jens Bedke

Pharmacol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disitamab Vedotin plus Toripalimab - New Players in Urothelial Carcinoma.
Jens Bedke

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
Laurence Albiges, Thomas Powles, Anand Sharma, Balaji Venugopal, Jens Bedke

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis